Merel Ritskes member of the - 3RCC Scientific Advisory Board

8 August 2018

The 3RCC Scientific Advisory Board (SAB) is responsible for providing scientific expertise to the 3RCC, evaluating grant applications and evaluating the progress and functioning of the center. The 3RCC SAB is composed of internationally recognized experts on 3Rs having expertise on 3Rs.

On the 27 March 2018, the Swiss 3R Competence Centre (3RCC) was founded to promote the principles of 3R in the areas of research and education. It represents an association of academia, industry, regulators, government and animal welfare association including eleven Higher Education Institutions from Switzerland, the Swiss association of pharmaceutical industry (Interpharma), the Swiss Federal Food Safety and Veterinary Office (FSVO) and, the Swiss Animal Protection. The 3RCC also benefits from the support from the Swiss State Secretariat for Education, Research and Innovation (SERI), as it represents a scientific centre of national importance working on a non-commercial basis according to article 15 of the Federal Act on the Promotion of Research and Innovation (RIPA).

Situated in Bern, the 3RCC’s objectives are to:

Promote research by subsidizing scientific projects of high quality and care for animals;
Develop an educational strategy targeted at different educational programs; and
Build a professional communication capacity available for all stakeholders interested in animal experimentation and 3Rs.

In addition, the 3RCC will be responsible for monitoring the progress made regarding the implementation of the principles of 3Rs in Switzerland.

Merel Ritskes is a member of the theme Reconstructive and regenerative medicine.

Want to know more about these subjects? Click on the buttons below for more news.

RIHS Health Evidence Research Reconstructive and regenerative medicine

Related news items

650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

Increased role of patients after bowel cancer treatment

30 July 2020

Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.

ERC Proof of Concept grant received by Ronald van Rij

30 July 2020

Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.

Hypatia fellowship Call is open

30 July 2020

The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.

Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.

29 July 2020

These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.

Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process

28 July 2020

''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.